At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,029 enrolled
Drug / intervention
exenatide +1 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)
In Brief
A Phase 3 clinical trial evaluating exenatide and glimepiride for Type 2 Diabetes Mellitus. Completed, enrolled 1,029 participants across 114 sites in 14 countries.
Detailed Summary
This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesAustria, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Mexico, Poland, Spain, Switzerland, United Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartSep 2006
Primary CompletionMar 2011
TodayJul 2026
First PostedAug 2, 2006
Enrollment StartSep 1, 2006
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 19.9 years ago
Interventions
exenatidedrug
subcutaneous injection (5mcg or 10mcg), twice a day
glimepiridedrug
oral tablet (titrated to maximally tolerated dose), once daily